BR112015016169A2 - caracterizando produtos de drogas relacionados a acetato de glatirâmero - Google Patents
caracterizando produtos de drogas relacionados a acetato de glatirâmeroInfo
- Publication number
- BR112015016169A2 BR112015016169A2 BR112015016169A BR112015016169A BR112015016169A2 BR 112015016169 A2 BR112015016169 A2 BR 112015016169A2 BR 112015016169 A BR112015016169 A BR 112015016169A BR 112015016169 A BR112015016169 A BR 112015016169A BR 112015016169 A2 BR112015016169 A2 BR 112015016169A2
- Authority
- BR
- Brazil
- Prior art keywords
- glatiramer acetate
- drug
- medicament
- drug substance
- featuring
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749228P | 2013-01-04 | 2013-01-04 | |
| US201361819481P | 2013-05-03 | 2013-05-03 | |
| PCT/US2014/010103 WO2014107533A2 (en) | 2013-01-04 | 2014-01-02 | Characterizing a glatiramer acetate related drug product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015016169A2 true BR112015016169A2 (pt) | 2017-07-11 |
Family
ID=51061235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015016169A BR112015016169A2 (pt) | 2013-01-04 | 2014-01-02 | caracterizando produtos de drogas relacionados a acetato de glatirâmero |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140193827A1 (enExample) |
| EP (1) | EP2941274A4 (enExample) |
| JP (1) | JP2016504039A (enExample) |
| KR (1) | KR20150111945A (enExample) |
| CN (1) | CN105228651A (enExample) |
| AU (1) | AU2014204043A1 (enExample) |
| BR (1) | BR112015016169A2 (enExample) |
| CA (1) | CA2896957A1 (enExample) |
| CL (1) | CL2015001915A1 (enExample) |
| EA (1) | EA201591251A1 (enExample) |
| HK (1) | HK1216299A1 (enExample) |
| IL (2) | IL239692A0 (enExample) |
| MX (1) | MX2015008754A (enExample) |
| PE (1) | PE20151980A1 (enExample) |
| SG (1) | SG11201505210RA (enExample) |
| WO (1) | WO2014107533A2 (enExample) |
| ZA (1) | ZA201505367B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| CN105377308B (zh) | 2013-03-14 | 2019-07-26 | 迈兰公司 | 醋酸格拉替雷响应生物标志物mRNA效力测定 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9995734B2 (en) | 2013-10-24 | 2018-06-12 | Mylan Inc. | Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| JP2018506275A (ja) | 2015-01-28 | 2018-03-08 | ジェネンテック， インコーポレイテッド | 多発性硬化症の遺伝子発現マーカー及び治療 |
| WO2017087866A1 (en) | 2015-11-20 | 2017-05-26 | Grand Valley State University | Nato3 mutant polypeptides and uses thereof |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| JP7276664B2 (ja) * | 2016-11-11 | 2023-05-18 | ロングエバーオン インコーポレイテッド | 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| CN115044684A (zh) * | 2022-06-22 | 2022-09-13 | 四川大学华西医院 | lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7429374B2 (en) * | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| WO2004028339A2 (en) * | 2002-09-27 | 2004-04-08 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| JP2009509142A (ja) * | 2005-09-19 | 2009-03-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法 |
| US8753833B2 (en) * | 2007-06-21 | 2014-06-17 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| EP2365825A1 (en) * | 2008-11-18 | 2011-09-21 | Crossbeta Biosciences B.V. | Cross-beta structures as carriers in vaccines |
| NZ598661A (en) * | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
-
2014
- 2014-01-02 MX MX2015008754A patent/MX2015008754A/es unknown
- 2014-01-02 EA EA201591251A patent/EA201591251A1/ru unknown
- 2014-01-02 HK HK16104285.8A patent/HK1216299A1/zh unknown
- 2014-01-02 SG SG11201505210RA patent/SG11201505210RA/en unknown
- 2014-01-02 JP JP2015551759A patent/JP2016504039A/ja active Pending
- 2014-01-02 EP EP14735255.3A patent/EP2941274A4/en not_active Withdrawn
- 2014-01-02 CA CA2896957A patent/CA2896957A1/en not_active Abandoned
- 2014-01-02 WO PCT/US2014/010103 patent/WO2014107533A2/en not_active Ceased
- 2014-01-02 BR BR112015016169A patent/BR112015016169A2/pt not_active IP Right Cessation
- 2014-01-02 KR KR1020157021141A patent/KR20150111945A/ko not_active Withdrawn
- 2014-01-02 CN CN201480008231.5A patent/CN105228651A/zh active Pending
- 2014-01-02 AU AU2014204043A patent/AU2014204043A1/en not_active Abandoned
- 2014-01-02 PE PE2015001246A patent/PE20151980A1/es not_active Application Discontinuation
- 2014-01-03 US US14/147,167 patent/US20140193827A1/en not_active Abandoned
-
2015
- 2015-06-29 IL IL239692A patent/IL239692A0/en unknown
- 2015-07-03 CL CL2015001915A patent/CL2015001915A1/es unknown
- 2015-07-24 ZA ZA2015/05367A patent/ZA201505367B/en unknown
-
2017
- 2017-05-28 IL IL252547A patent/IL252547A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015001915A1 (es) | 2016-11-11 |
| EA201591251A1 (ru) | 2016-05-31 |
| KR20150111945A (ko) | 2015-10-06 |
| IL252547A0 (en) | 2017-07-31 |
| IL239692A0 (en) | 2015-08-31 |
| SG11201505210RA (en) | 2015-07-30 |
| EP2941274A4 (en) | 2016-11-16 |
| PE20151980A1 (es) | 2016-01-15 |
| ZA201505367B (en) | 2016-11-30 |
| MX2015008754A (es) | 2016-04-11 |
| WO2014107533A2 (en) | 2014-07-10 |
| EP2941274A2 (en) | 2015-11-11 |
| CN105228651A (zh) | 2016-01-06 |
| US20140193827A1 (en) | 2014-07-10 |
| HK1216299A1 (zh) | 2016-11-04 |
| WO2014107533A3 (en) | 2015-01-29 |
| AU2014204043A1 (en) | 2015-08-13 |
| CA2896957A1 (en) | 2014-07-10 |
| JP2016504039A (ja) | 2016-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015016169A2 (pt) | caracterizando produtos de drogas relacionados a acetato de glatirâmero | |
| AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| MX2023001878A (es) | Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t. | |
| MX2023012263A (es) | Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico. | |
| BR112013003160A2 (pt) | tratamento de diabetes com células precursoras endócrinas pancráticas | |
| AR092027A1 (es) | Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares | |
| BR112017027498A2 (pt) | anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença. | |
| BR112017008251A2 (pt) | usos de um tecido de um porco transgênico que compreende um gene a(1,3) galactosiltransferase, cmah e ß4galnt2 interrompido e de um produto relacionado com a pele, métodos para preparação de um material de transplante para xenoenxerto, para produção de um composto de interesse e para produzir um reagente de cultura de células, e, reagente de cultura de células | |
| EP4349854A3 (en) | Pd1-cd28 fusion proteins and their use in medicine | |
| NZ630568A (en) | Methods and means for the production of ch3 domain-comprising molecules | |
| BR112017012927A2 (pt) | partícula compósita, processo cosmético e métodos para a preparação de uma partícula compósita | |
| WO2014066915A3 (en) | Methods and compositions to produce ss-rnai activity with enhanced potency | |
| UA116060C2 (uk) | Спосіб одержання продукту на основі глатирамеру ацетату | |
| UY36870A (es) | Análogos de insulina novedosos | |
| BR112014026053A2 (pt) | método de preparo de para-xileno a partir de biomassa | |
| BR112014027905A2 (pt) | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. | |
| BR112015009229A2 (pt) | composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada | |
| BR112018012070A2 (pt) | método para a produção de tecidos/ órgãos utilizando células sanguíneas | |
| BR112014032940A2 (pt) | ésteres de carboidratos como indutores de expressão de genes | |
| MX2016001238A (es) | Formulacion de una composicion sanguinea rica en plaquetas y/o factores de crecimiento, con proteinas gelificadas, y metodo de preparacion de la misma. | |
| IL246525B (en) | Pomegranate derived cell culture and methods for preparing and using the same | |
| BR112017008033A2 (pt) | composição farmacêutica para administração oral e respectivo processo de preparação | |
| BR112017001696A2 (pt) | composições de célula-tronco e métodos de produção de células-tronco para aplicações terapêuticas | |
| BR112015028737A2 (pt) | métodos para a produção e/ou purificação de hormônios | |
| BR112015029081A2 (pt) | Célula hospedeira myceliophthora thermophila expressando uma enzima beta-xilosidase recombinante, enzima beta-xilosidase recombinante expressada por meio da mesma, composição, uso de célula hospedeira, enzima beta-xilosidase ou composição e métodos de produção de açúcares fermentescíveis e de produção de bioproduto a partir de biomassa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |